Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).

Florian Gerhardt,David Petroff,Valentin Blank,Albrecht Böhlig,Florian van Bömmel,Christian Wittekind,Thomas Berg,Thomas Karlas,Johannes Wiegand

Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).

2020

Florian Gerhardt
David Petroff
Valentin Blank
Albrecht Böhlig
Florian van Bömmel
Christian Wittekind
Thomas Berg
Thomas Karlas
Johannes Wiegand

Background: Licensed therapies for nonalcoholic fatty liver disease (NAFLD) do not yet exist, but clinical trials are testing treatment options. Inclusion criteria often require liver biopsy showin...

Keywords:

Internal medicine
Liver biopsy
Endocrinology
nonalcoholic steatohepatitis
treatment options
Gastroenterology
in patient
Diabetes mellitus
Clinical trial
Medicine
Nonalcoholic fatty liver disease
Biopsy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations